Different ICIs act in different phases and sites of immune response, i.e., CTLA-4 is implicated in the priming phase within local/regional lymph nodes, while PD-1/PD-L1 works on the effector phase at tumor microenvironment level [5]. The gene discussed is PDCD1; the disease is neoplasm.